Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Liabilities and Shareholders Equity: 2020-2024

Historic Liabilities and Shareholders Equity for Apellis Pharmaceuticals (APLS) over the last 5 years, with Dec 2024 value amounting to $885.1 million.

  • Apellis Pharmaceuticals' Liabilities and Shareholders Equity rose 17.39% to $1.1 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $3.6 billion, marking a year-over-year increase of 4.24%. This contributed to the annual value of $885.1 million for FY2024, which is 12.21% up from last year.
  • Per Apellis Pharmaceuticals' latest filing, its Liabilities and Shareholders Equity stood at $885.1 million for FY2024, which was up 12.21% from $788.7 million recorded in FY2023.
  • In the past 5 years, Apellis Pharmaceuticals' Liabilities and Shareholders Equity registered a high of $960.6 million during FY2020, and its lowest value of $760.2 million during FY2022.
  • Its 3-year average for Liabilities and Shareholders Equity is $811.3 million, with a median of $788.7 million in 2023.
  • Per our database at Business Quant, Apellis Pharmaceuticals' Liabilities and Shareholders Equity dropped by 13.78% in 2022 and then grew by 12.21% in 2024.
  • Over the past 5 years, Apellis Pharmaceuticals' Liabilities and Shareholders Equity (Yearly) stood at $960.6 million in 2020, then fell by 8.20% to $881.8 million in 2021, then declined by 13.78% to $760.2 million in 2022, then rose by 3.75% to $788.7 million in 2023, then rose by 12.21% to $885.1 million in 2024.